Wnt/b-catenin signaling is frequently activated in cancer cells by stabilizing mutations of b-catenin or loss-offunction mutations of the APC tumor suppressor gene. We have analysed the role of b-catenin in the pathogenesis of hepatoblastoma (HB), an embryonic liver tumor occurring mainly in children under 2 years of age. Sequence analysis of the b-catenin NH 2 -terminal domain in 18 epithelial and mixed HBs revealed missense mutations in the GSK3b phosphorylation motif or interstitial deletions in 12 tumors (67%). In the remaining cases, no truncating mutation of APC could be evidenced. Immunohistochemical analysis of b-catenin in 11 HBs demonstrated nuclear/cytoplasmic accumulation of the protein in all tumors analysed, with predominant nuclear b-catenin immunostaining in undierentiated cells. Membranous b-catenin localization was preserved only in fetal-type tumoral hepatocytes and was associated with E-cadherin expression. Moreover, we show that b-catenin is aberrantly overexpressed in a large spectrum of tumor components, including hepatocyte-like cells at various dierentiation stages and heterologous elements such as squamous, osteoid and chrondroid tissues, and in occasional other mesenchymally-derived cells. These data strongly suggest that activation of b-catenin signaling is an obligatory step in HB pathogenesis, and raise the possibility that it interferes with developmental signals that specify dierent tissue types at early stages of hepatic dierentiation. Oncogene (2000) 19, 498 ± 504.
Introduction
Hepatoblastoma (HB) is the most frequent childhood liver cancer, but it is relatively uncommon when compared with other solid tumors in this age group (Weinberg and Finegold, 1983) . HBs originate from immature liver precursor cells and presents morphologic features recapitulating some of the developmental aspects of the liver. Pure epithelial HBs consist of fetal hepatocytes and various amounts of embryonal hepatocytes or small anaplastic (undierentiated) cells, showing occasional macrotrabecular patterns. Mixed epithelial-mesenchymal HBs additionally contain primitive mesenchyme and specialized derived components such as myo®broblastic, chondroid, and osteoid tissues, and teratoid HBs are admixed with a variety of heterologous structures of epithelial or mesenchymal origin (Stocker and Conran, 1997) . Little is known on the molecular basis of HB pathogenesis. Although most HBs are sporadic, some are associated with the Beckwith-Wiedemann syndrome or with familial adenomatous polyposis (FAP) (Weinberg and Finegold, 1983) . It has been shown that FAP patients carry germline mutations in the APC tumor suppressor gene (Polakis, 1999) , and biallelic inactivation of APC has been reported not only in FAP-associated HBs, but also in sporadic cases (Giardiello et al., 1996; Kurahashi et al., 1995; Oda et al., 1996) . Loss of function mutations in APC leading to intracellular accumulation of b-catenin are mainly responsible for the early progression of colorectal cancers (Kinzler and Vogelstein, 1996) . b-catenin is an essential eector of the Wnt signaling pathway (Cadigan and Nusse, 1997) , and this multifunction protein plays important roles in both intercellular adhesion and cell dierentiation (Aberle et al., 1996) . Furthermore, it has been recently demonstrated that overexpression of b-catenin induces malignant transformation of immortalized epithelial cell lines (Kolligs et al., 1999; Orford et al., 1999) . The NH 2 -terminal domain of b-catenin contains a phosphorylation motif for GSK3b and ubiquitination consensus sequences (Aberle et al., 1997; Yost et al., 1996) , and it is critical in regulating b-catenin stability. Upon Wnt signaling, GSK3b activity is inhibited, bcatenin is stabilized and translocated to the nucleus where it interacts with DNA binding transcription factors T-cell factor (Tcf) and lymphoid enhancer factor (Lef) and activates the transcription of target genes (Cadigan and Nusse, 1997) . The ®nding of somatic mutations in the NH 2 -terminal domain of bcatenin in dierent carcinomas has implicated abnormal activation of Wnt/b-catenin signaling as a crucial event in malignant transformation of a variety of epithelial cells (reviewed in Polakis, 1999) . In hepatocellular carcinoma, b-catenin mutations have been evidenced in 18 ± 26% of cases (de La Coste et al., 1998; Miyoshi et al., 1998) , and mutational activation of b-catenin has been associated with high cell proliferation (Tran van Nhieu et al., 1999) and decreased rate of allelic losses (Legoix et al., 1999) .
Recently, mutations and interstitial deletions in bcatenin exon 3 have been reported in 48% of hepatoblastomas and HB-derived cell lines (Koch et al., 1999) and abnormal nuclear overexpression of the protein has been evidenced in three HBs (Blaker et al., 1999) . It is not known, however, whether b-catenin activation may be triggered by dierent mechanisms in HBs, and whether b-catenin is dierentially expressed in the large spectrum of immature epithelial and mesenchymal tissues present in these tumors. To address these questions, we screened surgical specimens from 18 epithelial and mixed HBs for mutations in the b-catenin NH2-terminal domain and we used an immunohistochemical approach to investigate the subcellular distribution of b-catenin in various tumor cell types.
Results and discussion

Deletions and missense mutations of b-catenin in 18 HBs
A total of 38 tumor specimens including pure epithelial and mixed HBs from 18 patients (Table 1) was screened for b-catenin gene alterations over exons 2 ± 4. PCR ampli®cation of genomic DNA extracted from one to six tumor areas revealed additional bands smaller than the normal 1.1 kb product in 6 HBs ( Figure 1A ). Sequence analysis of the abnormal fragments showed that all deletions involved exon 3, some extending into exon 4 ( Figure 1B and Table 1 ). The presence of an identical stretch of two to ®ve nucleotides at the 5' and 3' junction in most cases has been previously noted in rare cases of colorectal cancer and might indicate the involvement of a mechanism of homologous recombination. RT ± PCR analysis con®rmed the presence of aberrant bcatenin transcripts of the expected size in HB5 and HB7 (data not shown). In HB11, no abnormal band was detected on agarose gel, but an identical 24 bp deletion was found in ten out of 90 sequences analysed after cloning the PCR products from two independent DNA extracts ( Figure 1B ). These data, together with the reduced intensity of the small versus normal-sized PCR product in some cases, could re¯ect contamination of the samples by normal cells or polyclonal expansion of these tumors. At Western blot analysis, a mutant b-catenin bearing a deletion of 138 aminoacids was more abundant than WT b-catenin in HB5 ( Figure  1C ), con®rming that exon 3 deletion stabilized the bcatenin mutant.
In the remaining tumors, we found missense mutations of b-catenin at codons 32, 34, 41 or 45 in ®ve tumors, including a case associated with BeckwithWiederman syndrome (HB13), but not in a case with FAP history (HB1) ( Table 1 ). The somatic nature of the mutations in four cases was established by sequencing DNA from matched normal tissue. In most cases, identical b-catenin status was observed in several samples of the same tumor, but in HB2 and HB8, mutations were detected in only two of three samples, suggesting clonal heterogeneity of these tumors. In summary, we show that 12 of 18 HBs (67%) harbored genetic alterations in the b-catenin gene (Table 1 ). It is noticeable that the prevalence of b-catenin mutations was somewhat lower (48%) in recent studies of a larger series of HB samples (Koch et al., 1999) . The limited number of cases analysed here, clonal heterogeneity of some HBs, or selective survival advantage of cells bearing activating mutations of b-catenin at preoperative chemotherapy might be evoked. A remarkable feature in HB is the high prevalence of interstitial deletions involving b-catenin exon 3, while missense mutations are prevalent in adulthood hepatocellular carcinomas (de La Coste et al., 1998; Legoix et al., 1999; Miyoshi et al., 1998) . It might re¯ect dierent mutagenic conditions associated with environmental factors or tissue dierentiation.
Stabilization and nuclear translocation of b-catenin is known to be associated with the activation of Tcf/ Lef target genes (Siegfried et al., 1994) . To evaluate the biological eect of the mutations, four b-catenin mutants (D32N in HB6, G34E in HB9, T41A in HB13 and D14-45 in HB15) and WT b-catenin cDNAs were transfected into 293 human embryonal kidney cells together with the Tcf-responsive reporter construct pTOPLUC or its mutated counterpart pFO-PLUC (Korinek et al., 1997) . As shown in Figure 2 , Tcf-dependent transcription was strongly activated Nuclear/cytoplasmic expression of b-catenin in epithelial and mesenchymal neoplastic cell types in HB To evaluate the impact of b-catenin mutations on the expression and cellular distribution of the protein in HB, we examined tumor tissues of 11 HBs (HB1 to HB11) and matched normal livers by immunohistochemistry. In normal liver, the protein localizes predominantly at the cell borders, with uniform linear membranous staining in hepatocytes, and intense membranous and cytoplasmic staining in interlobular bile ducts ( Figure 3A ). In contrast, most neoplastic tissues from all HBs examined displayed strong nuclear and cytoplasmic expression of b-catenin, including all four tumors which were not found to bear mutations in the NH2-terminal domain of the protein (Table 2; see  also Table 1 ). Nuclear/cytoplasmic staining was observed in a variable, frequently high percentage of cells in all tumorous tissues of epithelial origin, while no expression was observed in ®broblastic tissue surrounding the epithelial lobules (data not shown). Strong nuclear b-catenin signals were seen in small (anaplastic) and embryonal cells and in macrotrabecular patterns, particularly in invasive cells in the intravascular compartment ( Figure 3C ) or at invasion fronts ( Figure 3G ). Previous observations in hepatocellular carcinoma have similarly shown increased nuclear accumulation of b-catenin at the invasive front and in vascular invasions (Tran van Nhieu et al., 1999) . Moreover, lung metastasis from HB11 exhibited similar nuclear staining as invasive cells in the parental tumor (compare Figure 3d with 3c) . Importantly, nuclear bcatenin staining was found in only 5% of the cells in the original tumor, correlating with the low percentage of abnormal b-catenin alleles found in PCR experiments, while in lung metastasis 30% of cell nuclei were labeled.
The fetal pattern was present in all HBs and exhibited uniform cytoplasmic staining of b-catenin in most cases, with frequent membranous staining ( Table  2 ). In addition, three fetal-type tumors (HB3, HB4 and HB10) showed focal nuclear activation of b-catenin in scattered cells, whereas the remainder of the tumorous nodule displayed only membranous staining ( Figure  3b , shown as example). In these cases, no genetic alteration of b-catenin exon 3 could be evidenced in dierent tumor areas. Microdissection of speci®c cell , 1999; Voeller et al., 1998) . In mixed and teratoid HBs, nuclear/cytoplasmic accumulation of b-catenin was detected with varying staining intensities in heterologous elements of epithelial and mesenchymal origin, such as squamous, endodermal, chondroid, and osteoid tissues (Table 2 and Figures 3F ± H) . While some mesenchyme such as myo®broblasts and adipocytes were not labeled, focal nuclear b-catenin signals were occasionally detected in skeletal muscle ( Figure 3H ), and cytoplasmic/nuclear b-catenin expression was seen within osteoid and chondroid components in three tumors ( Figure 3F and Table 2 ). Osteoid tissue develops within areas of immature stroma and is generally considered as a mesenchymal element, but there is evidence suggesting that it might be produced through a process of epithelial dierentiation (Desdouets et al., 1995; Stocker and Conran, 1997) . In mixed HBs, the ®nding of identical b-catenin gene alterations within dierent tumor areas suggests that mutational activation of the oncogene occurred in a common precursor cell. However, dierent mechanisms might lead to nuclear translocation of b-catenin, as the deleted allele in HB7 was detected as a minor PCR product (see Figure 1a) , while 70% of tumor cells in all components harbored nuclear b-catenin signals (Table 2 ).
Analysis of APC
Previous studies of colorectal cancers have shown mutually exclusive distribution of APC and b-catenin mutations (Sparks et al., 1998) . We therefore screened the APC gene for truncating mutations in four HBs in which no mutation of b-catenin had been evidenced, including a FAP-associated tumor (HB1). As shown in Figure 4 , no aberrant polypeptide form was detected in these tumors after PCR ampli®cation of the Mutation Cluster Region (MCR) with two primer pairs and in vitro transcription-translation of the products (Olschwang et al., 1997). Similar data were reported in a recent study of 52 HBs (Koch et al., 1999) . However, we cannot exclude the existence of mutations unrelated to premature stop codons or located in other regions than MCR, as observed previously (Oda et al., 1996) . Alternatively, other cellular defects in the Wnt signaling cascade might be involved.
Immunohistochemical analysis of E-cadherin in HBs
Because alterations of E-cadherin disrupting the Ecadherin/b-catenin complex have been shown to promote accumulation of b-catenin in cytoplasmic and nuclear compartments (Sadot et al., 1998) , we next examined the expression of E-cadherin in dierent HB subtypes by immunohistochemistry. In normal liver cells, E-cadherin immunoreactivity was detected exclusively at the lateral membrane of the hepatocytes ( Figure 3I) . A weak membranous staining and occasional cytoplasmic localization of E-cadherin were seen in the fetal patterns in all HBs as shown in Figure  3J . No staining or occasional slight cytoplasmic/ nuclear staining was detected in embryonal hepatocytes and other cell types, in which b-catenin was localized exclusively in the cytoplasm and the nucleus. Thus, in more primitive cell types, marked nuclear accumulation of b-catenin correlated with the absence of detectable membranous expression of the interacting protein Ecadherin. The question of whether other cadherin(s) are expressed in embryonal cells in HB and in the developing liver deserves further studies.
Conclusions
The high prevalence of b-catenin gene alterations in HB, while b-catenin mutations were found in around 20% of hepatocellular carcinomas (de La Coste et al., 1998; Legoix et al., 1999) but no mutation was evidenced in cholangiocarcinoma (Y Wei and M-A Buendia, unpublished data) indicates that dierent mechanisms might operate in malignant transformation of distinct hepatic cell types. HBs develop during prenatal development from the primitive hepatic blastema, and it has been postulated that epithelial and mesenchymal elements in mixed HBs might develop from the same pluripotent stem cell. Our data, showing nuclear overexpression of b-catenin in all HBs analysed and in both epithelial and mesenchymal HB components, underscore the crucial role of deregulated Wnt/b-catenin signaling in malignant transformation of hepatic precursor cells. Interestingly, activation of b- 
Materials and methods
Patients and tumor tissues
Tumor specimens from 11 patients diagnosed with hepatoblastoma (HB1 ± HB11) and matched normal liver tissues were obtained from surgical liver resections at the BiceÃ tre Hospital, Le Kremlin-BiceÃ tre, France and seven others were collected at the University of Padova, Padova, Italy. All patients except two (HB14 and HB17) had received preoperative chemotherapeutic treatments. In one case (HB11), a lung metastasis which developed 1 year after surgical resection of the primary tumor was included in the study. Genomic DNA was extracted from frozen samples taken in one or several tumor areas by standard proteinase K digestion and phenol/chloroform extraction. Total RNA was prepared from the samples for which tissues were available using RNA-PLUS RNA extraction solution (Quantum Biotechnologies). For histological studies, multiple tumor samples and matched normal liver for each patient were ®xed in 10% neutral buered formalin, embedded in paran and stained with hematoxylin, eosin and saron. In each case, the sex and age of the patient at diagnosis, associated conditions, tumor histological types, vascular invasion and distant metastasis, and follow-up were recorded.
Mutational analysis of b-catenin
The 5' region of the b-catenin gene (from exon 2 to exon 4) was ampli®ed by PCR on genomic DNA as described previously (Tran van Nhieu et al., 1999) . For RT ± PCR analysis, cDNA was synthesized on 5 mg of total RNA with MMLV Superscript reverse transcriptase (GIBCO ± BRL) and random hexamers (Pharmacia), and cDNA was subjected to PCR reactions as above. Size-fractionated PCR products were puri®ed using a Qiaex II gel extraction kit (Qiagen). PCR products were sequenced using the T7 sequenase PCR product sequencing kit (Amersham/USB) or the SequiTherm EXCEL II DNA sequencing kit (Epicentre Technologies). For each tumor, independent PCR and sequencing experiments were carried out on dierent DNA samples to exclude PCR errors, and sequencing reactions were performed with forward and reverse primers to con®rm b-catenin mutations.
To search for mutations in the APC gene, a PCRtranscription-translation (PTT) method was used to detect premature translation arrest (Powell et al., 1993) . Genomic DNA was ampli®ed by PCR using two primer pairs (I and II) as described previously (Olschwang et al., 1997) .
Constructs and transfection experiments
The plasmid clone 405 containing full-length b-catenin cDNA (GenBank #Z19054) (HuÈ lsken et al., 1994) served as a template to construct b-catenin mutants using a two rounds PCR method (Wei and Ganen, 1998) . Nucleotide mutations were introduced into primers used in PCR (detailed sequences are available upon request). PCR fragments were veri®ed by sequencing, then mutant and WT b-catenin cDNAs were cloned in pcDNA3.
293 cells were cultured in DMEM supplemented with 10% bovine serum and penicillin-streptomycin. Cells were transfected by calcium phosphate coprecipitation using 0.5 mg of expression vector for mutants or WT b-catenin and 0.5 mg of the reporter plasmid pTOPLUC or pFOPLUC (Korinek et al., 1997) . The plasmid pCH110 expressing b-galactosidase (Pharmacia) was used as a control of transfection eciency. Cells were harvested 48 h after transfection, lysates were obtained and luciferase activity was measured using Lumat LB 9501 (Berthold).
Protein analyses
Cellular proteins were extracted from tumorous and normal liver tissues with Laemli buer (60 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol and 0.1% bromophenol blue) in the presence of 100 mM DTT. Lysates were fractionated on 10% SDS-polyacrylamide gels and transferred to Hybond-C extra (Amersham). The membranes were probed with an anti-bcatenin monoclonal antibody (1 : 6000 dilution) (Transduction Laboratories). Immune complexes were detected with alkaline phosphatase-conjugated goat anti-mouse antibodies and enhanced chemiluminescence (Tropix).
The PCR products of the APC gene were transcribed and translated in vitro using the TNT T7 coupled reticulocyte lysate system (Promega) in the presence of 35 S-labeled methionine. The samples were incubated at 308C for 90 min and analysed in 10% SDS-polyacrylamide gels.
Immunohistochemistry
Representative blocks of tumor tissues were selected in each case to carry out the immunostaining analysis of b-catenin and E-cadherin on serial sections. The standard avidin-biotinperoxidase complex (ABC) method was employed for immunostaining. Tissue sections were dewaxed in xylene and rehydrated in alcohol and distilled water. Antigen retrieval was performed by micro-wave oven heating (265 min) in EDTA 1 mM, pH8, followed by detergent treatment for 20 min. Nonspeci®c staining was blocked by bovine serum albumin for 20 min. Sections were incubated at room temperature with the primary antibodies for 30 min, then with biotinylated secondary antibodies. In control experiments, the primary antibody was omitted. Endogenous peroxidase activity was blocked by incubating sections with 0.3% hydrogen peroxide and the peroxidase reaction was developed with 0.01% hydrogen peroxide in 0.05% 3, 3'-diaminobenzidine (Sigma) solution. Monoclonal anti-b-catenin antibody (diluted 1 : 500) (Transduction Laboratories) and anti-E-cadherin antibody (1 : 250) (Takara Biochemical) were used as primary antibodies. Subcellular distribution and relative expression levels of b-catenin were evaluated in each HB component.
